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ABSTRACT
The aminoacyl-tRNA synthetases are a family of enzymes involved in the
process of translation, more specifically, ligating amino acids to their cognate tRNA
molecules. Recent evidence suggests that aminoacyl-tRNA synthetases are capable of
aminoacylating proteins, some of which are involved in the autophagy pathway. Here,
we test the conditions under which E. coli and human threonyl-tRNA synthetases, as
well as hisidyl-tRNA synthetase aminoacylate themselves. These reactions are ATP
dependent, stimulated by Mg2+, and are inhibited by increasing cognate tRNA
concentrations. These data represent the foundation for future aminoacylation
experiments, specifically delving into the relationship between the autophagy pathway
and the aminoacylation of proteins.
Additionally, we provide evidence of the inhibitory abilities of the anti-bacterial
β-lactone obafluorin on both E. coli and human threonyl-tRNA synthetases. Further, we
also show that the benzoate obafluorin analog EHTS-1 significantly inhibits E. coli
threonyl-tRNA synthetase but not the human enzyme. These data could be useful in
determining the potential for obafluorin and EHTS-1 as anti-bacterial and possibly antiangiogenic drugs.
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CHAPTER 1: INTRODUCTION
1.1. The Primary Function of Aminoacyl-tRNA Synthetases
1.1.1. Aminoacyl-tRNA Synthetases Are Instrumental in Translation
Translation, the process of converting the language of nucleic acids into a
sequence of amino acids, is crucial for all forms of life and is dependent on amino acids
being charged onto their cognate tRNA molecules with fidelity to the genetic code.
Aminoacyl tRNA synthetases (ARS) are a class of enzymes whose canonical function is
to ligate an amino acid onto the 3’ end of the corresponding tRNA molecule, assisting in
the translation of the universal genetic code. Due to this pivotal role in the translational
process, ARS are conserved across all the kingdoms of life1.
ARSs are divided into two classes based on several criteria. Class I ARSs are
mostly monomeric, bind tRNA in the minor groove of their acceptor stems, and attach
the amino acid to the 2’ hydroxyl group of tRNA while class II ARSs are mostly dimeric
or multimeric, bind tRNA in the major groove of their acceptor stems, and attach the
amino acid to the 3’ hydroxyl group of tRNA2–5. Class I synthetases tend to interact with
the less polar and larger amino acids while class II synthetases tend to interact with the
more polar and smaller amino acids. Active site architecture also plays a role in
synthetase classification; class I synthetases contain a Rossmann fold, which is shared
with kinases and dehydrogenases, while class II synthetases have a six-stranded
antiparallel β-sheet fold surrounded by α-helices in their active sites2,4. Research
indicates that the separate classes of ARSs may have originated from opposite strands of
the same ancestral gene6,7.
1

ARSs add amino acids to their cognate tRNA molecules in a two-step reaction3,
shown below:
I)

Amino acid + ATP ⇌ Aminoacyl-AMP + PPi

II)

Aminoacyl-AMP + tRNA ⇌ Aminoacyl-tRNA + AMP

Figure 1. The Mechanism of the Aminoacylation Reaction8. Adapted from Li et al., 2015.

In the first step, the ARS ‘activates’ the amino acid as the carbonyl group of the amino acid
attacks the α-phosphate group of ATP, producing an aminoacyl-adenylate intermediate and
a pyrophosphate (PPi) molecule (Figure 1). The aminoacyl-adenylate intermediate remains
non-covalently bound to the synthetase following the first of the two-step reaction. In the
second step, the 2’ or 3’ hydroxyl group of the adenine of the tRNA molecule’s CCA
acceptor stem will attack the carbonyl carbon of the amino acid in the aminoacyl-adenylate,
releasing the aminoacylated tRNA molecule and an AMP molecule (Figure 1). This
reaction is crucial for protein translation, because the formation of a peptide bond between
2

two free amino acids is thermodynamically unfavorable3. When coupled with the
hydrolysis of ATP to AMP and PPi, the ΔGᵒ’ for the formation of aminoacyl-tRNA is close
to zero, which then allows the hydrolysis of PPi to 2Pi to drive the reaction forward.
Because of this hydrolysis, the equivalent of 2 ATP molecules are consumed in the
aminoacylation reaction.
Because of their pivotal role in carrying out the genetic code, aminoacylation
reactions must occur with a high rate of fidelity to minimize translational errors.
Mischarged amino acids and translational errors have been associated with cell death in
microbes and disease in humans9–11. ARSs can distinguish amino acids with discrimination
factors from 10,000-100,000, making errors in only 1 of 40,000 aminoacylation
reactions12,13. This is facilitated by the ‘double-sieve model’ editing process, first
postulated by Fersht in 1979, by which larger amino acids are first discriminated by the
active site of the enzyme before smaller near-cognate amino acids are filtered out by a
secondary editing domain14,15. Fersht published in 1976 that valyl-tRNA synthetase
(VARS) was capable of forming a threonyl adenylate but would not catalyze the formation
of threonyl-tRNAVal 16. The editing process for the smaller near-cognate amino acids will
either be pre-transfer, where the near-cognate aminoacyl adenylate is hydrolyzed, or posttransfer, where the bond between the mischarged tRNA and the near-cognate amino acid
is hydrolyzed. Enzyme kinetics and the presence of tRNA have been determined as
deciding factors in whether pre- or post-transfer editing will occur, with pre-transfer editing
occurring only when the rate of transfer is significantly slow17.
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Despite performing their canonical function of aminoacylating tRNA, noncanonical functions have been discovered for many of the ARSs. These non-canonical
functions include regulation of both glucose and amino acid metabolism, organ
development, angiogenesis, inflammatory responses, stress responses, apoptosis, and
immune responses18. These secondary functions can also be carried out by alternatively
spliced or proteolytically cleaved fragments of the full length protein19.
1.1.2

Aminoacyl-tRNA Synthetases in Disease
Given the essential role of ARS in protein translation, it is unsurprising that

disrupting ARS function often results in abnormal cellular homeostasis and disease.
ARSs must not only charge tRNA with amino acids, they must do so with high fidelity,
and problems with either ARS function or editing could manifest with a phenotype. High
levels of mischarged amino acids have been shown to cause toxic effects in both
prokaryotic and eukaryotic cells9–11,20. A study of the effects of increased amino acid
levels on an editing-defective LeuRS mutant E. coli strain demonstrated that increased
mischarged-tRNA levels inhibited the growth of affected cells11. Several different
cytoplasmic ARS have been linked to tumor progression, due in part to their crucial
function in protein synthesis, supporting cancer proliferation and suppressing apoptotic
signals21,22.
Both dominant and recessive ARS mutations have been linked to a variety of
human diseases, which often involve neurological dysfunction9,23. Dominant ARS
mutations are associated with the peripheral neuropathy known as Charcot-Marie-Tooth
disease (CMT), while recessive mutations often cause profound neurodevelopmental
4

disease characterized by microcephaly and epilepsy9,23. CMT is an inherited disease of
the peripheral nervous system that causes degeneration of distal motor and sensory
neurons in a length dependent manner24. This eventually leads to muscle weakness and
atrophy in the legs and arms9,24. In 2003, Antonellis et al. discovered the first ARS
mutations associated with CMT, identifying four glycyl-tRNA variants25. Since then,
mutations in lysyl-tRNA synthetase, alanyl-tRNA synthetase, tyrosyl-tRNA synthetase,
histidyl-tRNA synthetase (HARS) and tryptophanyl-tRNA synthetase have been linked
to CMT9,26. Although it may seem likely that a unifying pathogenic mechanism links
ARS to CMT, some reports suggest that reduced aminoacylation and defective global
protein synthesis may not be the underlying cause26,27.
In addition to dominant ARS mutations linked to CMT, a number of recessive
and compound heterozygous mutations have been linked to severe neurodevelopmental
phenotypes that often include microcephaly. Microcephaly is a condition where the brain
does not develop properly, resulting in a smaller head circumference28. This can cause
impaired cognitive development, slowed speech and motor functions, seizures, balance
issues and other neurological problems in patients. Several novel VARS variants have
recently been identified in patients displaying microcephaly, which was also linked to
early-onset epilepsy23. The families of these patients are largely consanguineous, where
VARS had previously been identified as a candidate ‘disease gene’29. The identified
variants are dispersed throughout the VARS coding sequence, many of which were
predicted by comparison to T. thermophilus VARS to affect aminoacylation substrate
recognition or protein structure. Though modeling in zebrafish and yeast
5

complementation assays indicate that the underlying mechanisms of these mutations are
likely a decrease of protein function, that has yet to be tested explicitly30.
1.1.3

Threonyl-tRNA Synthetase
Threonyl-tRNA synthetase (TARS) is a class II ARS that charges threonine (Thr)

onto tRNAThr

31

. Like most class II synthetases, TARS functions as a dimer. Each

monomer has 4 domains: 2 N-terminal domains, the catalytic domain, and the anticodon
binding domain31. The catalytic core of the enzyme contains the active site that is
responsible for the recognition of Thr and ATP, the synthesis of the adenylate
intermediate, and the transfer of the charged amino acid to tRNAThr. Zinc serves as a
cofactor for TARS, and is found near its ATP binding site32. This ion is coordinated by
a water molecule and three residues of the protein, and is necessary for TARS
function31,32. The positive charge of the Zinc ion allows it to interact with hydroxyl
groups of amino acids, which allows TARS to distinguish between the Thr and Valine
(Val), which are structurally similar but differ in a hydroxyl group. The N2 domain of
TARS is involved in the hydrolysis of erroneously aminoacylated Ser-tRNAThr
complexes as a part of TARS’ ‘fine sieve’ post-transfer editing mechanism15,32,33.
In addition to this editing function, TARS is one of the several ARS that have been
related to angiogenesis, which is the process of blood vessel growth from the existing
vascular network34,35. TARS is secreted out of the cell via an unknown mechanism to
stimulate angiogenic extracellular signaling events34. Chicken embryos treated with
exogenous TARS display expanded vasculature in chorioallantoic membrane assays, and
application of TARS inhibitors in both zebrafish and endothelial cell tube formation assays
6

decrease cell migration, supporting the pro-angiogenic effects of TARS34,36. This
secondary function in angiogenesis likely plays a role in the association between ARS and
tumor progression, as inducing angiogenesis is one of the hallmarks of cancer37.
1.2 Enzyme Kinetics
1.2.1

Enzyme Kinetics
Enzymes are essential for life, and thus it is important for us to understand them

and the rates at which they work. Enzyme kinetics seeks to understand the affinities that
substrates have for their enzymes and the maximum reaction rate that an enzyme can
achieve38. In 1913, Leonor Michaelis and Maud Menten hypothesized that there was a
general theory of enzyme rates, with several assumptions. They assumed that enzyme (E)
and substrate (S) reversibly associate in forming an enzyme substrate complex (ES), which
then forms product (P) in the second step of reaction, as shown in the equation:

Next, the steady-state assumption assumes that [ES] reaches and stays at a constant value
in this system, meaning that ES is formed at a rate equal to the sum of ES dissociating to
E+S and ES being converted into E+P. Finally, Michaelis-Menten kinetics assumes that
the rate of back reaction (k -2) is small relative to the rate of the reaction catalyzed by the
enzyme (k2) (because enzymes can catalyze both the forward and reverse reactions). To
account for this we measure initial reaction velocities, where the enzyme has maximum
substrate concentrations and no product, minimizing the back reaction. This results in the
Michaelis-Menten equation:
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In this equation Vmax is the maximum velocity that can be reached by a certain
concentration of enzyme at saturating enzyme conditions, v is the reaction velocity and Km
is the substrate concentration at ½ of the reaction’s Vmax. Km is approximately inversely
related to the affinity that a substrate has for its enzyme, depending on the rates of ES
association (k1) and dissociation (k -1), and the rate of E+P formation (k2) according to the
following equation:

The Michaelis-Menten equation can be represented graphically with a Michaelis-Menton
plot, with [S] on the x-axis and v on the y-axis (Figure 2)

Figure 2. An example Michaelis-Menten plot showing Vmax, Km, v, and [S]39.

Because of the fact that the Vmax value for a Michaelis-Menten plot depends on the
experimental enzyme concentration Vmax is often converted to the enzyme’s turnover
number (kcat), which is the number of substrate molecules converted into product per
enzyme over time38. Experimentally, a Michaelis-Menten plot is derived from many
8

individual progress curves. By plotting product produced over time in a progress curve and
taking the slope from that curve (v), we can use this data as an individual point in our
Michaelis-Menten curve. After making many progress curves at many different substrate
concentrations, we can combine them to make the curve.
Adding inhibitors to the Michaelis-Menten reaction conditions can change the
apparent Vmax and Km values for the reaction depending on the type of inhibitor added
(Table 1).
Table 1. The four main types of inhibitors, their effects on the Vmax and Km values of a MichaelisMenten Plot, and the explanation for their effects38.

Type of Inhibitor Effect on Vmax
Competitive

None

Pure noncompetitive

Decrease

(Inhibitor binding
doesn’t change
substrate binding)

Mixed noncompetitive

Decrease

(Inhibitor may
preferentially bind
the E or ES complex)

Uncompetitive

Decreased

Effect on Km Explanation
Though the inhibitor will bind and
inhibit its substrate, increasing
substrate
concentration
will
prevent it will outcompete it. This
means that with enough substrate
the enzyme can still reach Vmax,
resulting in an increased Km
apparent.
None
Non-competitive inhibitors will
lower the number of enzyme
molecules available to perform the
reaction (lowering Vmax) without
changing the enzyme’s affinity for
its substrate (Km)
May decrease Depending on the inhibitor’s
affinity for the E or ES complexes,
Km
Km may decrease. Mixed
inhibitors will lower Vmax by
lowering the amount of active
enzyme.
Since uncompetitive inhibitors
Decreased
only interact with the ES complex,
this increases the enzyme’s
affinity for substrate through
LeChatlier’s principle (decreasing
Km). Vmax is also decreased
because IES complex formation

Increased

9

does not
formation.

lead

to

product

Using a combination of kinetic and structural data for a given enzyme, one could discern
the type of inhibition that a particular inhibitor exerts on its target enzyme40. In addition to
classification based on their mechanism of interacting with their target enzymes, some
inhibitors are also classified by their time-dependence or the binding strength of the
inhibitor41. Slow binding inhibitors bind or dissociate from their target enzymes slowly,
complicating the process of determining the affinity of the inhibitor for its target enzyme.
There are several different mechanisms of slow binding inhibition aside from the classic
reversible mechanism of41:

A slow binding inhibitor can act through an induced fit mechanism, where it will form an
initial binary complex (governed by the rates k3 and k4) before the enzyme undergoes a far
slower isomerization step, as shown below41:

Slow binding inhibitors can also act through mechanisms of conformational selection,
where either the enzyme or the inhibitor will isomerize between multiple forms in solution,
and only one of these isomers will interact with its binding partner. In these cases, the slow
isomerization limits the rapid formation of the EI complex. Only the mechanism for

10

enzyme isomerization is shown, because small molecule inhibitors do not often undergo
this isomerization41.

Because it takes time for the free and bound versions of the inhibitor to reach an
equilibrium, progress curves of slow binding inhibitors can display two different velocities.
These velocities are vi, the initial velocity of the reaction before the inhibitor starts to
interact with the enzyme (which is identical to that of the uninhibited reaction), and vs, the
steady state velocity after the free and bound inhibitor states have reached equilibrium
(Figure 3).

Figure 3. The effects of a slow binding inhibitor on a progress curve. Two progress curves, one without
an inhibitor and one with a slow binding inhibitor. The two slopes of the slow binding inhibitor curve are
labeled as vi and vs.

11

To combat this, when collecting experimental progress curve data researchers can preincubate the enzyme with the inhibitor prior to adding other reaction reagents. This will
only work for some inhibitor types and needs to be done in the absence of substrate in the
case of competitive inhibitors.
Some inhibitors bind to their target enzyme with such an affinity that the
assumptions used to calculate Ki values are no longer valid41. Such affinity is usually the
result of having very slow dissociation rates for the EI complex. Slow binding inhibitors
are often tight binding inhibitors as well. In these cases, the inhibitor will display a slow
rate of association for the E+I complex (kon), but an even slower dissociation rate (koff)
from the E+I complex. This allows the inhibitor to have a high affinity for its target enzyme
despite having a very slow rate of association41.
1.2.2

Inhibitors of Threonyl-tRNA Synthetase
There are several known inhibitors of TARS. Borrelidin is a macrolide-

polyketide, a large cyclic 18-membered lactone ring (Figure 4).

Figure 4. The Structure of two TARS inhibitors, Borrelidin and the Borrelidin Derivative BC194 42.

Produced by Streptomyces rocheii, borrelidin has been shown having anti-malarial, antiangiogenic, anti-fungal, and anti-tumor effects, in addition to inhibitory effects on TARS43–
12

47

. Borrelidin is a slow, tight binding inhibitor of TARS that displays non-competitive

mechanisms of interaction, and will severely denature the enzyme over time40,48. This
means that borrelidin inhibits TARS more the longer they’re incubated together, and that
once bound it has a low rate of dissociation from the enzyme. Borrelidin binds close to the
zinc ion in the active site of E. coli TARS, interacting with Thr-307, His-309, Cys-334,
Pro-335, Leu-489, and Leu-49340. Because of its inhibitory effects on TARS, borrelidin
has undesired cytotoxic effects. BC194 is a borrelidin derivative that exhibits decreased
cellular toxicity compared to that of borrelidin42. BC194 has a 4-membered carbon ring at
carbon 17 instead of the 5-membered ring seen in borrelidin (Figure 4).
Obafluorin is a β-lactone, first isolated from Pseudomonas fluorescens in
198449,50 (Figure 5).

Figure 5. The Chemical Structure of the TARS Inhibitor Obafluorin.51

Obafluorin exhibits antibacterial activity against a range of bacteria, including
Staphylococcus aureus, E. coli, and Enterobacter cloacae49. Despite being a β-lactone,
obafluorin exhibits relative susceptibility to hydrolysis via β-lactamases and is sensitive to
13

acidic conditions, which may indicate its instability compared to other β-lactones49,52.
Obafluorin was recently hypothesized to be an inhibitor of TARS and has not yet been
kinetically characterized52. A recent analysis of the obafluorin synthesis gene cluster
reveals a gene coding for a TARS paralog, ObaO (unpublished data from the Wilkinson
lab). This paralog may serve as a means of conferring obafluorin resistance to Pseudomoas
fluorescens, if it is not susceptible to TARS inhibition. ObaO differs from wild-type TARS
in a single cysteine (Cys) residue in its active site, which is substituted for a Val residue in
ObaO. This may indicate where obafluorin interacts with TARS and its mechanism of
inhibition. EHTS-1, a benzoate analog of obafluorin, may have inhibitory effects on TARS
like those hypothesized about obafluorin.
1.3 Aminoacylation as a Means of Post-Translational Modification
1.3.1 Post-Translational Modification Can Affect Protein Function
Proteins perform most of the processes that occur both intracellularly and
extracellularly in organisms. Though the diversity of the proteome and the protein
functions found throughout the proteome is large, the number of protein coding genes is
noticeably smaller53. This is accomplished through several different mechanisms ranging
from alternate promoter sequences and alternative splicing at the level of mRNA to posttranslational modification (PTM) at the level of protein. PTM is the covalent
modification of amino acid side chains or peptide linkages in a protein, and there are
hundreds of different PTMs that can occur across the proteome. PTMs can have many
different effects on a protein depending on both the target protein and the modification,
as well as the organism that the modification is occurring in, as the systems for PTM of
14

proteins are slightly different between prokaryotes and eukaryotes53,54. These effects
include but aren’t limited to changing the conformation of a protein, creating docking
sites for other proteins, changing the catalytic efficiency of an enzymatic protein, or
changing a protein’s cellular localization. PTMs are generally reversible, which is
important in the context of cellular signaling. A reversible PTM is more likely to be able
to change on a shorter time-frame and thus be more sensitive to cellular conditions than
an irreversible PTM or just protein levels in general, which would require protein
synthesis, degradation or re-localization to alter the signal that the protein is propagating.
PTMs like the proteolysis of peptide bonds in converting apoenzymes to holoenzymes
are irreversible, and thus are likely slower to respond to the changing cellular
environment than reversible PTMs like phosphorylation, acetylation, or ubiquitination53.
Though this reversibility is important in the context of cellular signaling, it can also make
it difficult to detect PTMs via methods like x-ray crystallography or mass spectrometry.
To prevent deacetylation or removal of similar post-translational modifications of
proteins experimentally, we could minimize sirtuin activity via sirtuin inhibitors like EX527 or sirtinol55,56.
1.3.2

Aminoacylation of Proteins
In 1997, Sylvie Gillet demonstrated that E. coli Methionyl Aminoacyl-tRNA

Synthetase (MetRS) could auto-aminoacylate57. This occurs via a covalent isopeptide
bond forming between the carboxylate of the amino acid and the ε-NH2 group of a lysine
residue. This modification lowered the enzyme’s ability to perform both ATP isotopic
exchange and to aminoacylate tRNAMet. Since then, other authors have demonstrated that
15

other ARS and ARS paralogs, like Bacillus stearothermophilus MetRS and an
Escherichia coli lysyl aminoacyl-tRNA synthetase (KARS) paralog, are capable of
aminoacylating other proteins (the KARS paralog is only known to aminoacylate E. coli.
elongation factor P) by the same mechanism of isopeptide bond formation with the εNH2 group of a lysine residue discussed in Gillet’s 1997 paper57–59.
In 2017, He et al. published NMR and mass spectrometry data detailing that all
twenty amino acids were identified as modifiers of lysine residues, using a documented
multi-specific amidase60,61. This suggested that the implications of the previous work in
protein aminoacylation were broader than expected, that all of the ARS are capable of
aminoacylating the ε-NH2 group of lysine residues, and that the modifications can be
removed by deacetylases like Sirtuin1 or Sirtuin3 via the normal deacetylation
mechanism60. Aminoacylation of proteins by ARS may represent a novel PTM that is
directly sensitive to amino acid levels and thus could be used as a mechanism for amino
acid sensing.
1.4 Autophagy
1.4.1

Overview of Autophagy
Autophagy is a process of cellular recycling, where macromolecules in the cell

are degraded to their fundamental parts62,63. There are several different subtypes of
autophagy, which are either selective (removing unnecessary or harmful materials from
the cell) or bulk (recycling cellular materials for the purpose of maintaining amino acid,
lipid, and nucleotide level homeostasis, triggered by starvation conditions) autophagy62.
There are three subtypes of autophagy: macroautophagy – the breaking down of damaged
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cell organelles or unused proteins, microautophagy – the direct and largely random
engulfment of cytoplasmic material into a lysosome, and chaperone-mediated autophagy
– the recognition and selection of cytosolic proteins that are then sent to lysosomes for
degradation62,64,65. Here, the term autophagy is used to refer to the process of
macroautophagy.
Autophagy is generally regulated by the ATG genes, over 30 of which have been
described66. These generally display distinct similarity across human and yeast genomes.
Autophagy begins with the construction of a vesicle precursor membrane called the
preautophagosome (PAS), which will grow and start to isolate macromolecules in the
cytoplasm as the structure becomes an autophagosome62,66,67 (Figure 6). This
autophagosome will then fuse with a lysosome, which contains enzymes that facilitate
the degradation of the contents of the autophagosome, thus facilitating the breakdown
and recycling of cellular constituents to their basic metabolites.

Figure 6. A visual representation of the autophagy pathway.
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Under starvation conditions, AMPK activates ULK1, which begins the nucleation
of

inositol-modified

membrane

components

into

the

PAS

through

ULK1

phosphorylating ATG13 and VSP34 in the PI3 kinase complex. In this step,
phosphatidylinositol 3-phosphate (PIP3) is added to the PAS. This structure is then
elongated by incorporating additional material to generate a phagopore/isolation
membrane. During this step, 1A/1B light chain 3b (LC3) conjugated to phosphatidyl
ethanolamine is incorporated into the structure along with the ATG12-ATG5-ATG16L1
complex, which assists in the conjugation of LC3 to phosphatidyl ethanolamine (PE)66.
As macromolecules start to become isolated by the growing phagophore, the generally
non-selective cargo of the soon-to-be autophagosome are tagged with poly-ubiquitin
chains that are selective for autophagy and are conjugated to LC3s with the help of
autophagy receptor and adaptor proteins66,68,69. The autophagosome is then fully
extended to complete the double walled vesicular structure that is the autophagosome.
Under conditions of amino acid sufficiency, mTORC1 (mammalian target of
rapamycin complex 1) (a protein complex containing the serine/Thr kinase mammalian
target of rapamycin) will phosphorylate and inhibit ULK1. mTORC1 is typically thought
of as one of the key regulators in the initiation of autophagy due to its relationship with
ULK1 and amino acid sensing. Despite this, it is poorly understood how mTORC1 reacts
to amino acid levels70. Currently, mTORC1 is only known to sense leucine and arginine
levels, but is not activated when deprived of the other 18 amino acids71. Analysis of
recent mass spectrometry data suggests that many components of the autophagy
machinery may interact with and are aminoacylated by various ARS60,72. For example,
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TARS, VARS and LARS have been suggested to aminoacylate ATG101 from the ULK1
complex, AMPK, and PI3 kinase. If these modifications had an effect on autophagy
levels, they would provide a rapid and direct means for the autophagy pathway to sense
the amino acid pool, as well as fill in the current gap in our knowledge of how mTORC1
serves as the amino acid sensor for the autophagy pathway.
1.4.2

Autophagy in Disease
Due to autophagy’s intrinsic link to the degradation of proteins and the

accumulation of macromolecules in the cell, autophagy and proteins related to the
autophagy pathway have been implicated in several different diseases66,73. These range
from neurodegenerative diseases like Crohn’s disease and Alzheimer’s disease to
diabetes66.
Crohn’s disease has been linked to duplications in the IRGM gene, which is
involved in the initiation of autophagy74,75. In addition, a single nucleotide polymorphism
in ATG16L1, a protein that mediates the conjugation of PE to LC3 in autophagy’s response
to pathogens, has also been associated with Crohn’s disease76–78. Several downregulating
variants in the ATG7 gene promoter, which regulates the expression of a key protein in
autophagosome formation, have been identified in patients with Parkinson’s disease79. An
upregulating variant in the ATG5 gene promoter has also been identified in a patient with
Parkinson’s disease80. Problems in the presenilin genes are the most common cause of
familial Alzheimer’s disease81. Deficiency in presenilin1 has been linked to the improper
translocation of the V0a1 subunit of the H+ -ATPase proton pump, resulting in improper
acidification of the lysosome and in turn abnormal autophagy. Finally, autophagy has been
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implicated in type 2 diabetes mellitus and the accumulation of human islet amyloid
polypeptide in pancreatic β cells, which cause functional impairment and loss of β cells66.
In addition to this, the autophagy pathway and its proteins have been demonstrated
as having both tumor suppressive and tumor proliferative effects depending on the phase
of tumorigenesis82. Autophagy upregulation can provide established tumors decreased
sensitivity to normally fatal environmental stimuli and can confer starvation resistance.
This aids in tumor progression, particularly in tumors undergoing the mesenchymal to
endothelial transition (MET)82,83. On the other hand, Becn1+/- mice (Becn1-/- mice are fatal)
can spontaneously develop several different types of malignancies82,84,85. The tumor
suppressive properties of autophagy in the early phases of tumorigenesis have several
possible mechanisms, including: suppression of reactive oxygen species (which have
genotoxic effects), destroying micronuclei (which arise in conditions of cell-cycle
perturbation), and controlling the levels of ras homology family member A (which is
involved in cytokinesis)82.
1.5 Thesis Objectives
Here we demonstrate the specific autoaminoacylation activity of both E. coli and
human TARS, as well as E. coli histidyl aminoacyl-tRNA synthetase (HARS) using
procedures modified from Yanasigawa et al., 201059. These reactions were ATP
dependent, and in the cases of the TARS enzymes were inhibited by tRNAThr and the
TARS inhibitors obafluorin and BC194. Here we also demonstrate the inhibitory effects
of obafluorin on both E. coli and human TARS activity and determine an IC50 value for
each enzyme.
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CHAPTER 2: EXPERIMENTAL PROCEDURES AND MATERIALS
2.1 Protein Purification
The assays that comprise the body of this thesis utilize purified ARS enzymes,
which were overexpressed in E. coli and purified using an ÄKTA purification system as
described in previous publications86–88. All purified proteins were expressed in pET
vectors and transformed into Veggie BL21(DE3) Competent Cells (Millipore) or
NovaBlue (Millipore) E. coli cells. Cells were grown in luria broth from stocks kept at 80ᵒC and expression of our target proteins was induced with isopropyl β-D-1thiogalactopyranoside (IPTG) at an OD600 of between 0.4-0.6 A. All our proteins were
His tagged, and thus were purified using a HisTrap HP 5 mL nickel-affinity column (GE
Healthcare) on an ÄKTA purifier system (GE Healthcare). Following purification, our
samples were dialyzed with SnakeSkin 10K MWCO Dialysis tubing (Thermo Scientific),
concentrated using Amicon Ultra 15 centrifugal filters (Millipore) and had their
concentrations determined using a Nano-Drop spectrophotometer system.
2.2 In vivo tRNAThr Transcription and Purification
To obtain purified tRNAThr for our kinetics and aminoacylation assays, tRNAThr
was overexpressed in E. coli and purified by gel electrophoresis and electrolution as
described in previous works from the Francklyn Lab89,90. E. coli tRNAThr was expressed
in BL21 E. coli cells, and purified via phenol chloroform extraction. The tRNAThr was
then precipitated overnight in 2.5x volume ethanol and 0.1x volume sodium acetate and
subjected to centrifugation. After washing the pellet with 75% ethanol, the pellet was
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resuspended in 10 mM HEPES pH 6. This sample was then mixed with 6X blue loading
dye

and

loaded

into

a

large

urea

gel

(6.5%

polyacrylamide

(19:1

acrylamide:bisacrylamide), 8 M urea, and 0.5 M sodium acetate pH 5). The gel was run
at 50 watts until the dye front almost ran off the gel, at which point the gel was imaged
via a UV light box and the tRNAThr band was identified. This band was excised, chopped
and placed into an electroeluter apparatus (Whatman/Schleicher & Schuell) overnight.
After electroelution, the purified sample was again precipitated with 2.5x volume ethanol
and 0.5x volume sodium acetate and then resuspended in TE6 buffer.
2.3 ARS Kinetics Assay
To measure the effects of obafluorin on TARS’ canonical tRNA charging
activity, an assay modified from Ruan et al., 2005 was used, where active enzyme was
incubated with its necessary substrates and its activity measured 14C labeled Thr and a
liquid scintillation counter40. Purified TARS protein (10 nM) was pre-incubated with
varying concentrations of obafluorin for 10 minutes. After pre-incubation, TARS and
obafluorin were added to a master reaction mixture with the final concentrations of 100
mM HEPES pH 7, 4 mM ATP, 10 mM MgCl2, 50 µM 14C labeled Thr (Moravek), and 5
µM tRNAThr. This mixture was then incubated for 10 minutes, with time points being
taken at 1, 2.5, 5, and 10 minutes. At each time point, three 5 μl aliquots were spotted
onto 5% TCA presoaked 3MM Whatman paper (Sigma-Aldrich). After letting the spots
dry, the Whatman paper was washed three times with 5% TCA, and once with 95%
ethanol. Whatman paper was dried and the counts on each square of paper analyzed with
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a liquid scintillation counter using Hydrofluor Liquid Scintillation Fluid (National
Diagnostics).
2.4 Autoaminoacylation Assay
To measure levels of ARS autoaminoacylation, enzyme was incubated with its
necessary substrates in a protocol modified from Yanasigawa et al., 2010, and was
visualized the reaction via gel electrophoresis and autoradiography (autorad)59. Purified
TARS (10 µM) was combined with 50 mM Tris HCL pH 7.5, 50 µM

14

C labeled Thr

(Moravek), 4 mM ATP, 10 mM MgCl2, 5 mM βME, and 5 µg/mL pyrophosphatase
(Thermo Scientific). This mixture was incubated in a 37˚C water bath for 2-6 hours, with
time points taken at key intervals. These time points were quenched in 4X SDS PAGE
sample buffer (200 mM Tris pH 6, 4% SDS, 4 mg/mL bromphenol, 4% βME, 40%
glycerol, and 0.004% pyronin Y) and then run on an 8% SDS PAGE gel. This gel was
fixed in a 50% methanol/10% acetic acid solution for 20 minutes and then dried in a 40%
glycerol/10% ethanol solution for 30 minutes. This dry gel was then imaged by exposing
a kodak phosphor screen (BioRad) to the gel for 62 hours and developing the screen on
a Pharos FX phosphoimager system (BioRad). Results were quantified using the volume
analysis tools in QuantityOne (BioRad).
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CHAPTER 3: AUTOAMINOACYLATION OF AMYINOACYL-TRNA
SYNTHETASES
3.1 Introduction
The current hypothesis of how ARSs could serve as a mechanism of sensing
amino acid levels in the autophagy pathway relies on ARSs being able to aminoacylate
proteins. This was already demonstrated in He et al., 2017, but has yet to be individually
validated for both TARS and HARS60. Among the many targets of each enzyme
identified in He et al., 2017, both TARS and HARS aminoacylate themselves, making
themselves the easiest targets to use to validate this function. Using an
autoaminoacylation procedure modified from Yanasigawa et al., 2010, the
autoaminoacylation abilities of several different ARSs were tested in various conditions,
addressing the substrates necessary for the reaction and the effects of tRNA on the
reaction.
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3.2 E. coli ARS Results
To validate the requirements for the E. coli TARS’ protein aminoacylation
reaction, autoaminoacylation assays were performed with varying concentrations of
enzyme, Mg2+, and ATP. These assays revealed that the reaction is dependent on the
presence of ATP, and is sensitive to Mg2+ concentrations. (Figure 7).

Figure 7. E. coli TARS is capable of autoaminoacylation. N = 2 An autoradiograph showing E. coli
TARS autoaminoacylation at 0 and 6 hours varying (from left to right) enzyme concentration (0 or 10 µM),
ATP concentration (0 or 4 mM) and Mg2+ concentration (0 or 10 mM).

Though there was no MgCl2 added to the reaction mixture for the ‘No MgCl2’ condition,
we did not test whether the reaction would occur with no Mg2+ present (for example
ensuring that there is no Mg2+ in our ATP salt), and thus cannot say whether the reaction
can occur without Mg2+.
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Following this, we were interested in the time frame of this reaction. To test this,
we performed an autoaminoacylation assay, taking time points at 0, 0.25, 0.5, 1, 2, 3, 4,
and 6 hours (Figure 8a). Graphing this autorad data reveals that the reaction reaches its
peak progress at 2 hours (Figure 8b). Following this, levels of aminoacylated TARS
decrease and eventually plateau around 4 hours.

Figure 8. The time frame of the E. coli TARS autoaminoacylation reaction. N = 2. a) An
autoradiograph showing eight time-points (increasing left to right) taken at during an E. coli TARS
autoaminoacylation assay. b) A progress curve for a six-hour long E. coli TARS autoaminoacylation assay
in units of autorad detected radiation (U).

26

With a better understanding of the kinetics of the reaction, we next wanted to
see the effects of increasing tRNAThr concentration on the rate of the aminoacylation
reaction. Adding 10 µM tRNAThr to an autoaminoacylation assay resulted in decreased E.
coli TARS autoaminoacylation (Figure 9a). Again, graphing this autorad data reveals that
tRNAThr greatly decreases the autoaminoacylation effects of E. coli TARS (Figure 9b).

Figure 9. tRNAThr decreases E. coli TARS autoaminoacylation. N=1
a) An autoradiograph showing eight timepoints (increasing left to right) of a three-hour long
autoaminoacylation assay without tRNA. b) An autoradiograph showing eight timepoints (increasing left to
right) of a three-hour long autoaminoacylation assay with 10 µM tRNA. c) Two E. coli TARS
autoaminoacylation progress curves, one with 10 µM tRNA, and one without, shown in units of autorad
detected radiation (U).
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Finally, the specificity of the E. coli TARS autoaminoacylation reaction was
tested. To test this, two side by side aminoacylation assays were run, one with TARS and
Thr, and the other with TARS and His. This assay revealed that the reaction is in fact Thr
specific, as there are only bands in the autorad in the timepoints that contain Thr (Figure
10).

Figure 10. E. coli TARS autoaminoacylation is Thr specific. N=1. An autoradiograph with two E. coli
TARS autoaminoacylation assays, one (the left four lanes) with Thr (50 µM), the other (the right four
lanes) with His (50 µM).
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After finding the requirements for E. coli TARS’ autoaminoacylation reaction
and confirming its specificity, E. coli HARS was tested to confirm the requirements for
its autoaminoacylation reaction. To test this, an autoaminoacylation assay with available
E. coli HARS was performed, varying concentrations of ATP. As anticipated, E. coli
HARS was also capable of autoaminoacylation, and like autoaminoacylation of E. coli
TARS, autoaminoacylation of E. coli HARS is also ATP dependent (Figure 11a). The
specificity of the HARS autoaminoacylation reaction was also tested via two side by side
autoaminoacylation reactions, one with His and the other with Thr. This showed that, like
E. coli TARS, E. coli HARS protein aminoacylation activity is specific to its cognate
amino acid (Figure 11b).

Figure 11. E. coli HARS is capable of specific autoaminoacylation with His. a) An autoradiograph
showing E. coli HARS autoaminoacylation at 0 and 6 hours varying (from left to right) enzyme
concentration (0 or 10 µM) and ATP concentration (0 or 4 mM). b) An autoradiograph with two E. coli
HARS autoaminoacylation assays, one (the left four lanes) with His (50 µM), the other (the right four
lanes) with Thr (50 µM).
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This set of experiments supported that both E. coli TARS and E. coli HARS are
capable of autoaminoacylation. These reactions have a reproducible time frame and are
both cognate amino acid specific and ATP dependent, likely occurring through the same
mechanism undergone in the aminoacylation of their cognate tRNA molecules.
3.3 Human TARS Results
To validate human TARS’ protein aminoacylation abilities and the conditions
under which it autoaminoacylates, autoaminoacylation assays were performed with
varying concentrations of Mg2+, and ATP. These assays did support human TARS being
able to autoaminoacylate, though there was some protein aggregation (Figure 12).

Figure 12. Human TARS is capable of autoaminoacylation. N=3. An autoradiograph showing human
TARS autoaminoacylation at 0 and 6 hours varying (from left to right) enzyme concentration (0 or 13 µM),
Mg2+ concentration (0 or 10 mM) and ATP concentration (0 or 4 mM).

Rather than showing up as a strong band at the molecular weight of human TARS (75 kDa),
there are strong bands barely in the very top of the gel, and a faint band at 75 kDa. These
results showed up consistently across all three of these experiments, and were not fixed
with increased reducing agent or increased time denaturing at 90ᵒC before SDS PAGE.
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Regardless, the data show that human TARS autoaminoacylation is ATP dependent, and
is sensitive to decreased Mg2+ concentrations. To test whether the TARS’
autoaminoacylation abilities are specific to Thr, two side by side autoaminoacylation
assays were run with human TARS, one with Thr and one with Val. This revealed that like
protein aminoacylation by E. coli TARS, protein aminoacylation via human TARS is
specific to Thr (Figure 13).

Figure 13. Human TARS autoaminoacylation is Thr specific. An autoradiograph with two human
TARS autoaminoacylation assays, one (the left four lanes) with Thr (50 µM), the other (the right four
lanes) with Val (50 µM).

These experiments also showed that the bands at the top of the autoradiograph are likely
aggregates of human TARS and that their formation is likely time dependent. Next, we
wanted to test the effects of tRNAThr on human TARS autoaminoacylation, which we
accomplished by running an aminoacylation assay with 10 µM tRNAThr and comparing it
to human TARS lanes without tRNAThr. Just like we see in E. coli TARS, the presence of
tRNAThr decreases TARS autoaminoacylation (Figure 14a). When counted via a volume
analysis tool in QuantityOne, we see that the in the presence of tRNAThr, human TARS
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autoaminoacylation only reaches 80% of that reached by the reaction without tRNAThr
present (Figure 14b). These experiments appeared to have less aggregated 14C labeled
TARS than previous experiments with the human enzyme. This may be due to increased
mixing of the reaction reagents during its 2-hour incubation at 37ᵒC.

Figure 14. tRNAThr decreases human TARS autoaminoacylation. N=3 a) An autoradiograph with three
human TARS autoaminoacylation assays, one (the left four lanes, time increasing left to right) with
tRNAThr (15 µM), one (the center lane) with no tRNA, and the last (the right four lanes, time increasing left
to right) with tRNAThr (15 µM). b) The average progress curve of human TARS in the presence of tRNAThr
compiled from three autoaminoacylation assays. This curve is normalized to the activity of a human TARS
autoaminoacylation assay without tRNAThr, incubated for two hours. Error bars represent the standard
deviation for each time point.

From these experiments we confirmed that human TARS is capable of
autoaminoacylation as published in He et al., 201760. Like the bacterial enzyme, this
reaction is both Thr specific and ATP dependent, but is more susceptible to protein
aggregation in our assay than the bacterial enzyme. Autoaminoacylation of human TARS
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is also decreased by tRNAThr. Human TARS’ specificity to Thr, dependence on ATP, and
susceptibility to increasing tRNA concentration all suggest that these reactions are likely
occurring through the same mechanism of TARS’ canonical function of tRNAThr
aminoacylation.
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CHAPTER 4: CHARACTERIZING THE INHIBITORY EFFECTS OF
OBAFLUORIN ON THREONYL-TRNA SYNTHETASE ORTHOLOGS.
4.1 Introduction
Obafluorin is a β-lactone with a nitrobenzene and an ortho-benzenediol on either
side of the β-lactone50. β-lactams and β-lactones are known for their potential as
antibiotics, due to the mechanism of penicillin (a β-lactam) in inhibiting cell wall
synthesis by preventing cross-linking of the forming peptidoglycans91. Obafluorin was
identified as an antibacterial agent in 1984, but it was not until a recent analysis of the
biosynthetic obafluorin operon that a possible mechanism of action was hypothesized for
its antibacterial effects49,50,52. Within obafluorin’s biosynthetic operon lies the gene
ObaO, which encodes a TARS paralog of the same name (ObaO). One hypothesis for the
function of this gene is that it may be an obafluorin resistant TARS paralog, as this would
be necessary for Pseudomonas fluorescens to still produce tRNAThr and thus have normal
protein translation if obafluorin did inhibit TARS.
Borrelidin, an 18-membered macrolide compound with a five-membered ring
attached to it at carbon 17, was isolated from Streptomyces rocheii in 194946. Since then,
its anti-malarial, anti-angiogenic, anti-fungal, and anti-tumor effects have been shown,
the mechanism of these being its inhibition of TARS43–47. Like borrelidin, obafluorin may
be a slow, tight binding inhibitor of TARS, but is yet to be kinetically characterized. To
test the possible inhibitory effects of obafluorin on both bacterial and human TARS, we
employed ARS kinetics assays and a wide range of obafluorin concentrations, allowing
us to calculate the IC50 values for both enzymes.
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4.2 Results
To validate obafluorin’s hypothesized inhibitory effects on E. coli TARS’
canonical function, four ARS kinetics assays were run, each with a different
concentration of obafluorin (0 nm, 10 nm, 100 nm, and 1 µM). Increasing obafluorin
concentration resulted in decreasing bacterial TARS activity, demonstrated by decreased
progress curve slopes (Figure 15).

Figure 15. E. coli TARS is inhibited by obafluorin. N=3 Pmol of tRNA charged over time for four
different ARS kinetics assays with E. coli TARS, each with a different concentration of obafluorin, shown
in the figure key on the right. Error bars represent the standard error for each time point.

To better understand the inhibitory potential of obafluorin on bacterial TARS, more ARS
kinetics assays were performed, but this time with seven different obafluorin
concentrations and the end goal of creating an IC50 curve for obafluorin on bacterial
TARS. Again, increasing obafluorin concentrations correlated with decreased bacterial
TARS activity (Figure 16). From these data collected with 10 nM E. coli TARS, an IC50
value of 1.325*10-7 M (132.5 nM) was calculated (Figure 16) (Table 2).
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Figure 16. Obafluorin’s IC50 with E. coli TARS. An IC50 curve for E. coli TARS with fractional
velocity plotted against molar obafluorin concentration on a logarithmic scale. This curve was calculated
from N=3 progress curve data with seven different obafluorin concentrations.

Table 2. Obafluorin IC50 values for E. coli and human TARS. Enzyme concentration, IC50 values and
R2 values from IC50 curves for both E. coli and human TARS. Experiments for IC50 curves were
performed with N=3.

E. coli TARS

Human TARS

Enzyme concentration

10 nM

5 nM

IC50

1.325*10-7 M (132.5 nM)

2.396*10-8 M (23.96 nM)

R2 value (non-linear fit,
variable slope, four parameters)

0.9682

0.9683

Obafluorin’s inhibitory potential on human TARS was then tested with seven ARS
kinetics assays, each with a different obafluorin concentration (figure 17a). From this
data collected with 5 nM human TARS, an IC50 value of 2.396*10-8 M (23.96 nM) was
calculated (Figure 17b) (Table 2).
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Figure 17. Obafluorin inhibits human TARS. a) Pmol of tRNA charged over time for seven different
ARS kinetics assays with human TARS, each with a different concentration of obafluorin, shown in the
figure legend on the right. Error bars represent the standard error for each time point. N=3 b) An IC50
curve for human TARS with fractional velocity plotted against molar obafluorin concentration on a
logarithmic scale. This curve was calculated from N=3 progress curve data with seven different obafluorin
concentrations.
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Finally, the inhibitory potential of a benzoate obafluorin analog, EHTS-1, was
tested for both bacterial and human TARS. ARS kinetics assays were performed with
three different EHTS-1 concentrations for both bacterial and human TARS, yielding
interesting results. EHTS-1 did not have a statistically significant inhibitory effect on
human TARS (Figure 18a). The bacterial enzyme on the other hand did have significantly
decreased activity in the presence of EHTS-1 (Figure 18b).

Figure 18. EHTS-1 inhibits E. coli TARS but not human TARS. a) Three ARS kinetics assay progress
curves with E. coli TARS, each with a different obafluorin concentration. Error bars represent the standard
error for each time point. Each curve was calculated from data of N=3. b) Three ARS kinetics assay
progress curves with human TARS, each with a different obafluorin concentration. Error bars represent the
standard error for each time point. Each curve was calculated from data of N=3.

Overall, many ARS kinetics assays across a range of obafluorin concentrations
indicate that obafluorin does inhibit both E. coli and human TARS. Additionally, the
benzoate obafluorin analog EHTS-1 did not have a statistically significant effect on
human TARS, but did result in a significant decrease in E. coli TARS activity.
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS
5.1: Autoaminoacylation
In this study, we validate and expand upon the finding of He et al., 2017, who
described that ARS are capable of aminoacylating proteins. We find that E. coli TARS
and HARS, as well as human TARS are capable of autoaminoacylation, and described
the conditions required for this reaction to occur. The ATP dependence, activity increase
in the presence of Mg2+, specificity for each ARS’s cognate amino acid and inhibition of
TARS autoaminoacylation by increasing tRNAThr concentrations suggest that this
reaction occurs through the same mechanism as ARS’s canonical tRNA charging
function. This differs from the mechanism of protein aminoacylation discussed in Vo et
al., 2018, where the protein ANKRD16 functions as a sink for Ser that has been
mischarged by AlaRS92. When graphing aminoacylated E. coli TARS over time we
observed a decrease in aminoacylated TARS after 3-4 hours of incubation (Figure 8b and
9b). This decrease in autoaminoacylation levels indicates that some of the isopeptide
bonds formed in the aminoacylation reaction will break over time, and the plateau in
aminoacylated TARS levels following it indicates that the reaction might reach an
equilibrium between aminoacylated and un-aminoacylated ARS. In 1997 Gillet et al.
demonstrated that aminoacylated MetRS displayed decreased aminoacylation
functionality, supporting this hypothesis that the reaction reaches an equilibrium between
unlabeled ARS and aminoacylated ARS that have decreased activity57.
Though these findings are important in and of themselves, their implications about
ARS as a means of post-translationally modifying proteins are far broader. If ARS are
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capable of aminoacylating proteins, not only does this mean there is a new mechanism for
PTM of proteins, there is also a new mechanism for PTM of proteins that is directly related
to the amino acid pool of the cell60. This would allow aminoacylation to function as a signal
for amino acid starvation or amino acid sufficiency conditions and play a role in the amino
acid metabolism of the cell. Among the many aminoacylated proteins identified in
Behrends et al. 2010, several pieces of the autophagy machinery are likely aminoacylated72.
These include ATK101 from the ULK1 complex, PRKAG1 and 2 from AMPK γ, and
ATG14, which is a part of the PI3K complex72,93. In a state of cellular amino acid
sufficiency, ARS could label these proteins to propagate the amino acid sufficiency signal
through the autophagy pathway, inhibiting it. In a state of cellular amino acid starvation,
ARS would not be able to aminoacylate these pieces of autophagy machinery, allowing
them to perform their typical function in the initiation of autophagy. Interestingly, ARS
aminoacylation of proteins seems to be conserved between both prokaryotes (E. coli) and
eukaryotes (humans). This points to this mechanism and PTM being very old, likely having
a diverse range of functions across the tree of life94.
One limitation to the methods employed in our study is the high background signal
seen in our autoradiographs. Even after ensuring that our k-screens were blanked, and both
the k-screens and cassettes were not radioactive, the background signal persisted in our
autoradiographs. The background signal is likely a consequence of long k-screen exposure
times (~60-80 hours) with a relatively weak radioisotope (14C). With a stronger
radioisotope we would see higher signal-to-noise ratio, which would allow QuantityOne to
set a lower background radiation level while still showing where the signal was
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concentrated on the screen. This does not diminish the impact of our findings, as there is a
clear and quantifiable difference between conditions where autoaminoacylation was
occurring and where it was not.
Alongside attempting to minimize background radiation in our autoradiographs,
we would also like to test the effects of the TARS inhibitors BC194 and obafluorin on the
autoaminoacylation reaction, as well as the effect of adding catalytically dead TARS
mutants to the reaction mixture. By varying the concentration of catalytically dead TARS
mutants in the reaction mixture, we could make a Michaelis-Menton curve for the reaction,
as the catalytically dead mutants act exclusively as substrates for the reaction.
These autoaminoacylation experiments have been a piece of a much larger work
that has the overarching goal of identifying the mechanisms underlying amino acid sensing
in the autophagy pathway. Here, we have provided control experiments that confirm the
results from Behrends et al., 2010 and He et al., 201760,72. We would like to continue
experiments like these by testing the ability of ARS to aminoacylate the components of the
autophagy machinery put forth in Behrends et al., 2010, for example TARS aminoacylating
a bacterially-expressed ULK1 catalytic domain construct72. Using immunoaffinity
purification methods we could selectively purify ULK1 or other crucial components of
autophagy machinery in both fed and starved conditions and compare whether the protein
is aminoacylated via mass spectrometry to determine whether the modification is a function
of the nutritional states of the cell. Alternatively, following immunoaffinity purification of
components of autophagy machinery from amino acid starved conditions we could
incubate the purified protein with select ARSs and either radiolabeled or ‘cold’ amino acid,
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and detect the aminoacylation of these proteins by SDS page and autoradiography or mass
spectrometry respectively.
Preliminary western blotting data indicates that leucine (Leu) or Thr depletion and
TARS knockdown via siRNA significantly increase phosphorylated ULK1 (p-ULK1) at
S555, indicating activation of autophagy. (Figure 19).

Figure 19. Amino acid depletion and TARS knockouts increase p-ULK1. a) Western blots against PULK1 (S555), TARS, P-AMPK, and β-tubulin in full media, and Thr and Leu deplete medias. b)
Quantified western blot data showing phospho-AMPK (pAMPK), pULK1, and TARS levels in Thr and
Leu starved media after 1 and 3 days. c) A bar graph showing normalized p-ULK1 levels from SKOV-3
cells in control media, Torin1 (an mTOR inhibitor) treated media, or amino acid starved media (EBSS)
transfected with either control siRNA or siTARS.

Using human ovarian cancer cell lines (SKOV and PC12), siRNA against specific ARS,
and amino acid rich and depleted medias, we will assess which ARSs and amino acids are
most important in the process of autophagy initiation, detecting changes between fed and
starved via well-validated autophagy assessment assays, including autophagy specific
dyes95, comparing free LC3 levels (a standard indicator of autophagy levels in the
autophagy literature) vs LC3 levels in autophagosomes96, or monitoring LC3 I maturation
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to LC3 II97. We expect these experiments to support the essential branched chain amino
acids being particularly crucial in the initiation of autophagy.
5.2: Obafluorin
In this study, we confirmed that obafluorin is an inhibitor of both E. coli and
human TARS, and calculated IC50 values for obafluorin with both enzymes (1.325*10-7
M (132.5 nM) at 10 nM enzyme concentration, and 2.396*10-8 M (23.96 nM) at 5 nM
enzyme concentration respectively) (Table 2). We also showed that ETHS-1, a benzoate
analog of obafluorin, did not have a statistically significant inhibitory effect on human
TARS, but did result in a significant decrease in E. coli TARS activity.
TARS inhibitors often display antibacterial activities, including obafluorin
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This means that there is some potential for obafluorin and obafluorin analogs as
antibacterial drugs, depending on their selectivity for the human and bacterial enzymes.
Though calculated for different concentrations of enzyme (10 nM for E. coli and 5 nM for
human), our preliminary data suggest that the human enzyme may have a higher affinity
(lower IC50) for obafluorin than the bacterial enzyme. These data need more replicates and
statistical support before publication, but if true, would indicate that obafluorin may not be
useful as an antibacterial drug for use in humans, but may prove useful as an antiangiogenic drug. TARS is among the several synthetases that have been implicated in
angiogenesis, which when dysregulated is one of the hallmarks of cancer34,37. As a
compound that has slightly more affinity to the human enzyme than the bacterial enzyme,
obafluorin may prove useful as an anti-angiogenic drug with minimal off-target, gutmicrobiota side effects. Alternatively, our data show that EHTS-1 had no significant
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inhibitory effects on the human enzyme, but did significantly inhibit the bacterial enzyme
(Figure 18). If supported with more replicates, enzyme concentrations and inhibitor
concentrations, EHTS-1 could prove useful as an antibacterial drug for human use in the
future.
This does bring up one drawback to our current data, the number of replicates
necessary for statistical support of our data. Particularly highlighted in our EHTS-1 data
with E. coli TARS (which shows that 100 nM EHTS-1 inhibited E. coli TARS significantly
more than 1 µM EHTS-1 did), and in our obafluorin and human TARS IC50 curve (where
the 5 µM obafluorin concentration had a negative fractional velocity), we need to repeat
our experiments with more replicates, different enzyme preps, and more inhibitor
concentrations to ensure accurate and reproducible IC50 values. Additionally, unpublished
data from the Wilkinson lab has identified a gene encoding a TARS paralog within the
cluster of genes involved with the obafluorin synthesis machinery. This enzyme, called
ObaO, is largely similar to bacterial TARS, but has a Cys residue substituted for a Val. We
hypothesize that this TARS paralog may be obafluorin resistant, and this Cys

Val

substitution may be important for obafluorin resistance. We have been provided pET28a
vectors that contain ObaO, ObaO with its Val substituted for a Cys, and E. coli TARS with
its Cys substituted for a Val by the Wilkinson lab, and in future experiments we plan to test
the effects of obafluorin on these three enzymes.
5.3: Closing Remarks
ARSs are a family of enzymes that are of critical importance for translation,
attaching a specific amino acid to its cognate tRNA molecule. Recent ARS developments
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range from elucidating their role in diseases from cancer to peripheral neuropathy, to
exploring them as a means to post-translationally modify other proteins. This function is
likely conserved across both prokaryotic and eukaryotic ARSs, opening up an incredibly
diverse array of protein targets for ARSs to aminoacylate. Additionally, the discovery of
new ARSs inhibitors that have different affinities for each ARSs ortholog offers unique
possible solutions to the many diseases associated with ARSs. Here we have helped
develop our understanding of ARSs as post-translational modifiers of pieces of the
autophagy machinery and the novel TARS inhibitor obafluorin, expanding the already
complex web of interactions and pathways that ARSs are involved in, and raising
valuable questions that warrant the continued study of this diverse group of enzymes.
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APPENDIX: CHARACTERIZING THE ACTIVITY OF VALYL-TRNA
SYNTHETASE MUTANTS
Intro:
As a result of ARSs integral role in protein translation and their growing list of
secondary functions, many ARS have been implicated in many different diseases, ranging
from cancer and autoimmune diseases to neurodegenerative diseases9,21. Both dominant
and recessive pathogenic variants have been identified in ARS genes from patients with
disorders presenting neurological features. These range from diseases with peripheral
neuropathies like Charcot Marie Tooth Syndrome98–100, to congenital visual impairment
with progressive microcephaly101, and developmental delays with progressive
microcephaly and intractable seizures102,103. Recently, several novel VARS variants were
identified in mainly consanguineous families, two families of which were previously
reported as VARS being a candidate ‘disease gene’29. Several of these mutant variants were
tested via yeast complementation assays and in zebrafish models, demonstrating that these
variants likely lead to a loss of protein function and that VARS deficiency mirrors some of
the main characteristics of the human disease. To supplement the yeast complementation
data and further support the recently identified VARS variants cause a loss of function, we
performed in vitro activity assays on patient-derived fibroblasts and lymphoblasts. Our
assays supported the hypothesis that these new VARS variants have a loss of function and
that they may be contributing to the phenotypes displayed by the patents. If it was the case
that the parents did not have 100% activity compared to control, this would suggest that
there is a threshold below which loss of aminoacylation activity causes disease phenotype,
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and mutations that allow aminoacylation function above this threshold will be nonpathogenic. Determining this threshold could be useful for predicting the possible
phenotypes that could manifest in a patient containing specific mutations.
Methods:
These protocols were modified from the aminoacylation protocol described in
Puffenberger et al. 2012. Control ATCC cells and patient derived cell samples were grown
in Dulbecco’s Modified Eagle Medium, high glucose (Gibco®) enriched with 10% heatinactivated Fetal Bovine serum (FBS) (Gibco®), 1% L-glutamine (Life Technologies), 1%
penicillin-streptomycin (Life Technologies) conditions for fibroblasts and RPMI 1640
Medium (Gibco®), enriched with 10% heat-inactivated FBS (Gibco®), 1% L-glutamine
(Life Technologies), 1% penicillin-streptomycin (Life Technologies) and 1% sodium
pyruvate (Life Technologies) conditions for lymphoblasts. Following washes with
Dulbecco’s phosphate buffered saline, cells were lysed in protease inhibitor cocktail
(Sigma), 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM dithioreitol, and 0.5% Triton X100 and protein concentration was measured via Bradford assay. Lysates were mixed to
make 100 mM HEPES pH 7.2, 30 mM KCl, 10 mM MgCl2, 107 µM total human placental
tRNA, 2 mM ATP, 50 µM
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C-labeled valine (282.8 mCi/mmol). These mixes were

incubated at 37 ᵒC with timepoints taken at 1, 2.5, 5 and 10 minutes of incubation. These
timepoints were quenched when spotted onto 3MM Whatman filter paper pre-soaked with
5% TCA. This filter paper was washed three times with 5% TCA, and once with 95%
ethanol before having its radiation quantified via liquid scintillation. The specific activity
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for each sample was calculated from linear fits of progress curve data, and was
subsequently corrected for total protein concentration.
Results and Discussion:
Using the above assay on the available patient lymphoblasts and fibroblasts, all
the patient cells tested showed decreased VARS activity (Figure 20).

Figure 20. Patient cells have decreased VARS activity. VARS and TARS activity levels measured from
control or patient cell cell lysates. Error bars represent the standard error for each data set. Fibroblast data is
in a), lymphoblast data is in b).

In

the

fibroblasts,

patients

4

and

5

(heterozygous

carrying

the

p.Leu78Argfs*35/p.Arg942Gln variants) each display significantly decreased activity
compared to control cells, approximately 25% and 12.5% respectively (Figure 20a).
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Looking at the lymphoblasts, Patients 1 and 2 (heterozygous carrying the
p.Leu434Val/p.Gly828Ser variants) had approximately 50% VARS activity compared to
their parents (who did not display the phenotype but were heterozygous carrying the wildtype allele and either the p.Leu434Val or p.Gly828Ser variant) (Figure 20b). Patient 9
(carrying homozygous p.Arg404Trp variant) had approximately 25% VARS activity
compared to the mother and father. The heterozygosity of each parent (having one wildtype allele and either p.Leu434Val or p.Gly828Ser each) raises the question as to whether
the parents have the same activity levels as a control cell line that is homozygous for wildtype VARS. If it was the case that the parents did not have 100% activity compared to
control, this would suggest that there is a threshold of aminoacylation activity for
displaying a phenotype, which could in turn be useful for predicting the possible
phenotypes that could manifest in a patient containing specific mutations.
These results support the variants expressed in the tested patient cells being loss
of function variants, and along with zebrafish and yeast complementation data collected
for these variants, suggest that these variants may be the mechanism underlying
neurological disease phenotypes displayed by these families30. This was among the first
kinetic assays of VARS in association neurological disease, and provides us some basis for
possible prediction of phenotypes that may be associated with ARS variants, better
understanding the phenotypes of the afflicted patients, and perhaps future therapies for the
observed phenotypes.
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